Johnson & Johnson (JNJ) is a leading drug manufacturers-general business based in the US. It opened the day at $168.625 after a previous close of $168.76. During the day the price has varied from a low of $167.15 to a high of $168.65. The latest price was $167.84 (25 minute delay). Johnson & Johnson is listed on the NYSE and employs 134,500 staff. All prices are listed in US Dollars.
Best for
Low-cost
Best for
Beginners
Best for
Funds
Best for
Range of markets
Since the stock market crash that started in February 2020, Johnson & Johnson's share price has had significant positive movement.
Its last market close was $162.97, which is 8.00% up on its pre-crash value of $149.93 and 49.29% up on the lowest point reached during the March 2020 crash when the shares fell as low as $109.16.
If you had bought $1,000 worth of Johnson & Johnson shares at the start of February 2020, those shares would have been worth $740.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,085.38.
| Open | $168.625 |
|---|---|
| High | $168.65 |
| Low | $167.15 |
| Close | $167.84 |
| Previous close | $168.76 |
| Change | $-0.92 |
| Change % | -0.5452% |
| Volume | 5,847,839 |
| 52-week range | $148.6678 - $177.7656 |
|---|---|
| 50-day moving average | $166.227 |
| 200-day moving average | $166.9251 |
| Wall St. target price | $186.44 |
| PE ratio | 24.6406 |
| Dividend yield | $4.14 (2.57%) |
| Earnings per share (TTM) | $6.691 |
Other fees apply. Your capital is at risk.
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | $10 | £3.10 £623.94 total |
Capital at risk |
 |
£0 | £0.01 | £1.55 £622.39 total |
Capital at risk |
 |
£0 | £50 | £3.10 £623.94 total |
Capital at risk |
|
£0 | £250 | £10.54 £631.38 total |
Capital at risk |
 |
£0 | £1 | £18.16 £639.00 total |
Capital at risk |
|
£9.99 per month | No minimum | £17.30 £638.14 total |
Capital at risk |
 |
£0 | No minimum | £6.21 £627.05 total |
Capital at risk |
 |
£36 per year | £20 | £17.26 £638.10 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Johnson & Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Johnson & Johnson shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Johnson & Johnson's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.
Johnson & Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson & Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Johnson & Johnson's PEG ratio in relation to those of similar companies.
Johnson & Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $31.5 billion (£23.3 billion).
The EBITDA is a measure of a Johnson & Johnson's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
| Revenue TTM | $91.4 billion |
|---|---|
| Operating margin TTM | 26.29% |
| Gross profit TTM | $54.3 billion |
| Return on assets TTM | 8.59% |
| Return on equity TTM | 26.54% |
| Profit margin | 19.55% |
| Book value | $26.694 |
| Market capitalisation | $434 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson & Johnson.
Johnson & Johnson's total ESG risk: 35.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson & Johnson's overall score of 35.8 (as at 01/01/2019) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Johnson & Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare Johnson & Johnson's total ESG risk score against those of similar companies.
Johnson & Johnson's environmental score: 3.79/100
Johnson & Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson & Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Johnson & Johnson's social score: 25.14/100
Johnson & Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson & Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Johnson & Johnson's governance score: 14.87/100
Johnson & Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson & Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Johnson & Johnson's controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Johnson & Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson & Johnson has a damaged public profile.
Wondering how that compares? Below are the controversy scores of similar companies.
Johnson & Johnson was last rated for ESG on: 2019-01-01.
| Total ESG score | 35.8 |
|---|---|
| Total ESG percentile | 72.38 |
| Environmental score | 3.79 |
| Environmental score percentile | 7 |
| Social score | 25.14 |
| Social score percentile | 7 |
| Governance score | 14.87 |
| Governance score percentile | 7 |
| Level of controversy | 4 |
Dividend yield: 2.57% of stock value
Forward annual dividend yield: 2.57% of stock value
Dividend payout ratio: 44.49% of net profits
Johnson & Johnson has recently paid out dividends equivalent to 2.57% of its share value annually.
Johnson & Johnson has paid out, on average, around 44.49% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.57% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 2.57% return on their shares, in the form of dividend payments. In Johnson & Johnson's case, that would currently equate to about $4.14 per share.
While Johnson & Johnson's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.
Johnson & Johnson's most recent dividend payout was on 8 March 2022. The latest dividend was paid out to all shareholders who bought their shares by 18 February 2022 (the "ex-dividend date").
Johnson & Johnson's dividend yield is perhaps best considered in relation to those of similar companies.
Johnson & Johnson's shares were split on a 2:1 basis on 13 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson & Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson & Johnson shares which in turn could have impacted Johnson & Johnson's share price.
Over the last 12 months, Johnson & Johnson's shares have ranged in value from as little as $148.6678 up to $177.7656. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson & Johnson's is 0.7364. This would suggest that Johnson & Johnson's shares are less volatile than average (for this exchange).
To put Johnson & Johnson's beta into context you can compare it against those of similar companies.
Subscribe to trending stock alerts for a chance to win
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
Ever wondered how to buy shares in Telefónica? We explain how and compare a range of providers that can give you access to many brands, including Telefónica.
Ever wondered how to buy shares in TSMC? We explain how and compare a range of providers that can give you access to many brands, including Taiwan Semiconductor.
Everything we know about the Mobileye IPO, plus information on how to buy shares.
Ever wondered how to buy shares in Banco Bilbao Vizcaya Argentaria? We explain how and compare a range of providers that can give you access to many brands, including BBVA.
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
This guide provides step-by-step instructions on how to buy Dent, lists some exchanges where you can get it and provides daily price data on DENT.
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
With no annual fee, the Halifax Cashback Credit Card could be a good option for those looking to earn something back on their spending.
Everything we know about the Polestar IPO, plus information on how to buy shares.
